Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
- First Online:
- Cite this article as:
- Kolesar, J., Huang, W., Eickhoff, J. et al. Cancer Chemother Pharmacol (2009) 64: 79. doi:10.1007/s00280-008-0845-0
- 101 Downloads
The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.
Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA).
Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman’s rank correlation = 0.30; p = 0.12).
RRM2 gene and protein expression varies by tumor type.